[{"orgOrder":0,"company":"Ridge Biotechnologies","sponsor":"Sutter Hill Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ridge Biotechnologies","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Ridge Biotechnologies \/ Sutter Hill Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Ridge Biotechnologies \/ Sutter Hill Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Ridge Biotechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Ridge Bio’s initial offerings include NativeLink enzymes, for site-specific conjugation of therapeutic proteins (e.g., for ADCs) without altering sequence or glycans, and ProTrigger linkers.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          September 09, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Sutter Hill Ventures

                          Deal Size : $25.0 million

                          Deal Type : Financing

                          blank